News | August 15, 2013

Mevion Medical Systems Secures $55 Million to Accelerate the Deployment of Its Cancer Treatment Technology

Mevion Medical Systems Funds S250 Deployment

August 15, 2013 — Mevion Medical Systems Inc. has secured $55 million to accelerate the deployment of its revolutionary Mevion S250 Proton Therapy System. The funds were raised from existing equity investors, including Caxton Heath Life Sciences, ProQuest Investments, Venrock and CHL Medical Partners, as well as from debt financing provided by Life Sciences Alternative Funding LLC (LSAF).

Proton particles have the intrinsic ability to deliver a more highly targeted treatment for the management of cancerous tumors and lesions as compared to traditional X-ray radiation therapy. This ability can provide less collateral damage to surrounding healthy tissue, making proton therapy a valuable treatment option for pediatric cancers and high-risk target locations. However, proton therapy has been limited to only a select few institutions because of the high-cost, large space requirements and operational complexities of legacy proton systems. The Mevion S250 is a proton therapy system that has changed this paradigm, delivering the same precise, non-invasive treatment capabilities and advantages of conventional systems but with a significantly reduced size, improved reliability, efficient clinical workflow and lower implementation cost. With a footprint similar to a modern X-ray radiation therapy device, the Mevion S250 brings accessibility, affordability and practicality to proton therapy.

“Mevion was founded to provide cancer centers and patients around the world with cutting-edge proton therapy technology on a scale, size and cost that is accessible and practical for today’s healthcare landscape,” said Joseph K. Jachinowski, chief executive officer of Mevion Medical Systems. “These additional funds will support the growth of our business operations in the U.S. and internationally.”

The Mevion S250 proton therapy system is the only single-room proton therapy system that is cleared by the U.S. Food and Drug Administration (FDA) for clinical use. The first Mevion S250 is installed at the S. Lee Kling Center for Proton Therapy at Barnes Jewish Hospital at Washington University Medical Center in St. Louis, Mo., and is currently undergoing clinical acceptance and commissioning in preparation for patient treatment later this year. With five centers under installation and construction and more than a dozen under planning, Mevion has established itself as a leading proton therapy supplier worldwide

For more information: www.mevion.com

 

Related Content

Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
MedStar Georgetown Conducts World's First Hyperscan Proton Therapy Treatment
News | Proton Therapy | April 27, 2018
For the first time, cancer patients in the Washington, D.C. metropolitan region have access to proton therapy, now...
First Patient Treated on Mevion's S250i Proton Therapy System
News | Proton Therapy | April 05, 2018
Mevion Medical Systems announced the treatment of the first patient in the world on the Mevion S250i Proton Therapy...
MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

Feature | Proton Therapy | March 06, 2018 | By Jeff Zagoudis
Proton therapy has experienced major growth in the last decade, but that growth seems to have slowed slightly in recent...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
RayStation Selected for India’s First Proton Center
News | Proton Therapy | February 01, 2018
February 1, 2018 – Apollo Hospitals, Asia´s foremost integrated healthcare provider, has selected RayStation for a ne
IBA Announces First Patient Treated with Proteus PLUS in The Netherlands
News | Proton Therapy | January 25, 2018
January 25, 2018 –  IBA (Ion Beam Applications SA) has announced that the University Medical Center Groningen (UMCG)
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
Overlay Init